Coherus Oncology, Inc.
CHRSHealthcare|Biotechnology|US
$0.77
+0.02 (+2.82%)
Tangible Book / Share
$0.10
Cash / Share
$0.68
Clinical Trials (28)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06457503 A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer | Nasopharyngeal Cancer Recurrent | P4 | Recruiting | 100 | Open-label | Toripalimab, Cisplatin, Gemcitabine, Carboplatin |
| NCT07140679 Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer | Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 | P2 | Recruiting | 40 | Open-label | Toripalimab |
| NCT07214987 PDT For Induction Therapy For Head And Neck Cancer | Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma | P2 | Recruiting | 26 | Open-label | Toripalimab-tpzi, Cisplatin, Docetaxel |
| NCT06940180 Toripalimab With Chemotherapy for Sinus Cancer | Sinonasal Cancer, Paranasal Sinus Neoplasms | P2 | Recruiting | 20 | Open-label | Toripalimab, Carboplatin, Docetaxel, Cisplatin |
| NCT06975293 STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas | Solid Tumor, Sarcoma | P1P2 | Recruiting | 107 | Open-label | STC-15 in combination with toripalimab, STC-15 monotherapy |
| NCT07423078 Window of Opportunity in Preserving Laryngeal Function Trial | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma | P2 | Recruiting | 87 | Open-label | Toripalimab, Carboplatin, Cisplatin, Paclitaxel |
| NCT06679985 A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | Hepatocellular Carcinoma | P2 | Active | 72 | RCT, Open-label | Casdozokitug, Toripalimab, Bevacizumab |
| NCT07281716 Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC | Metastatic Microsatellite Stable Colorectal Carcinoma | P1P2 | Recruiting | 24 | Open-label | Nadunolimab, Toripalimab |
| NCT07277322 Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases | Metastatic Colorectal Cancer, Liver Metastases | P1P2 | Recruiting | 24 | Open-label | Dupilumab, Toripalimab |
| NCT07209189 Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN) | Head and Neck Cancer, Squamous Cell Carcinoma | P2 | Recruiting | 75 | Open-label | Toripalimab + Chemotherapy, Toripalimab |
| NCT05635643 Study of CHS-114 in Participants With Advanced Solid Tumors | Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma | P1 | Active | 87 | RCT, Open-label | CHS-114, toripalimab |
| NCT06657144 A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors | Metastatic Solid Tumor, Advanced Solid Tumor | P1 | Recruiting | 154 | RCT, Open-label | CHS-114, Toripalimab, 5 Fluorouracil, Cisplatin |
| NCT02486939 A Long Term Safety Extension Study (CHS-0214-05) | Rheumatoid Arthritis, Plaque Psoriasis | P3 | Completed | 359 | Open-label | CHS-0214 |
| NCT02134210 Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) | Plaque Psoriasis | P3 | Completed | 521 | RCT, Double-blind | Etanercept, CHS-0214 |
| NCT02115750 Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA) | Rheumatoid Arthritis | P3 | Completed | 647 | RCT, Double-blind | Etanercept, CHS-0214 |
| NCT02489227 Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis | Plaque Psoriasis | P3 | Completed | 545 | RCT, Double-blind | CHS-1420, Adalimumab |
| NCT05359861 Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma | Hepatocellular Carcinoma | P2 | Terminated | 30 | RCT, Double-blind | Casdozokitug, Atezolizumab, Bevacizumab, Placebo |
| NCT05479045 A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients | Ovarian Cancer Stage IV, Ovarian Cancer Stage III | P2 | Withdrawn | — | Open-label | NY-ESO-1 Peptide vaccine, Toripalimab-tpzi |
| NCT07836049 PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC | Esophageal Squamous Cell Carcinoma | P2 | Not Yet Recruiting | 20 | Open-label | Toripalimab, Carboplatin + Paclitaxel |
| NCT05177770 Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | P2 | Terminated | 16 | Open-label | SRF617, etrumadenant, zimberelimab |
| NCT04374877 Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma | P1 | Completed | 145 | Open-label | CHS-388, Pembrolizumab, Toripalimab |
| NCT04336098 Study of SRF617 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | P1 | Completed | 85 | Open-label | SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab |
| NCT05757492 Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Advanced Solid Tumor, Non-Small Cell Lung Cancer | P1 | Terminated | 22 | RCT, Open-label | CHS-006 (anti-TIGIT), toripalimab (anti-PD-1) |
| NCT02650973 Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta | Healthy | P1 | Completed | 122 | RCT, Single-blind | CHS-1701, Pegfilgrastim |
| NCT02385851 Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim) | Bioequivalence | P1 | Completed | 116 | RCT, Double-blind | CHS-1701, Pegfilgrastim |
| NCT06389526 A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | P1 | Not Yet Recruiting | 48 | Open-label | CHS-1000, Toripalimab |
| NCT02418104 Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta® | Immunity, Humoral | P1 | Completed | 303 | RCT, Double-blind | CHS-1701, Pegfilgrastim (Neulasta) |
| NCT04662892 An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca | Febrile Neutropenia, Non-myeloid Malignancy | Unknown | 200 | — | Pegfilgrastim-Cbqv |